Siemens Healthineers: A €6 Billion Diagnostics Sale Could Unlock Value as Shares Sink to 52-Week Low

Siemens Healthineers shares slump to €35.43, 20% down in 2025, as analysts see 50% upside. Company weighs €6B diagnostics sale, prepares for Siemens AG spin-off by 2027.

The gap between where Siemens Healthineers trades and where analysts believe it should be has rarely been wider. At €35.43, the stock has slumped to its lowest level in a year, shedding roughly 20% of its value since January. Yet the consensus price target from 28 analysts sits at just over €54, with the most bullish forecasts reaching beyond €66. That disconnect reflects a company wrestling with short-term headwinds while pursuing a strategic overhaul that could fundamentally reshape its future.

The Diagnostics Dilemma

Behind the scenes, management is exploring a radical fix for the division that has become the group's biggest drag. Siemens Healthineers is weighing the sale of its struggling diagnostics unit to private equity buyers, a deal that could fetch around €6 billion. The business has been a persistent brake on performance — first-quarter revenues in the segment slipped by roughly 3%, with demand in China particularly weak.

A disposal would deliver two immediate benefits. It would relieve the company of an underperforming asset and, crucially, allow it to tackle a debt pile that currently stands at approximately €14 billion. The proceeds would provide significant firepower for deleveraging, giving the group cleaner financial footing as it prepares for life as a fully independent entity.

Preparing for Independence

That independence is coming into sharper focus. Siemens AG, the parent company, has laid out a clear timetable for shedding its remaining stake. At the annual general meeting in February 2027, shareholders will vote on a direct spin-off of the shares. The countdown has already begun, and Siemens Healthineers needs to be ready to stand alone.

A key piece of that preparation is now in place. Moody's has assigned an inaugural A3 rating with a stable outlook, giving the company an investment-grade credit profile that will support its future access to capital markets. The move signals that the rating agency sees the underlying business as fundamentally sound, even if the market is currently punishing the stock.

Currency and Tariff Headwinds

The market's pessimism is not without reason. External pressures are mounting from multiple directions. Around 40% of the group's revenues come from the United States, while the bulk of its costs are denominated in euros. That structural mismatch leaves earnings vulnerable to currency swings, which could shave up to €250 million from operating profits. On top of that, potential US tariffs represent a further risk of around half a billion euros.

The combination of heavy debt and these operational risks has rattled investors. The stock now sits exactly at its 52-week low, and the distance to the 200-day moving average has stretched to nearly 19%, a technical signal that underscores just how far the shares have fallen.

Analyst Conviction

Despite the gloom, Wall Street remains broadly constructive. Bernstein Research has welcomed the parent company's roadmap for separation, arguing that full independence will allow Siemens Healthineers to manage its capital allocation more efficiently. RBC Capital Markets has reiterated its "Outperform" rating, pointing to the operational separation that is already well advanced.

The bull case rests on the strength of the core imaging business and stable margins in laboratory diagnostics. Analysts see the current share price as reflecting temporary headwinds rather than structural weakness. With the relative strength index hovering near 32, the technical picture suggests the stock is deeply oversold, though whether that marks a genuine floor depends on what management delivers next.

What to Watch on May 7

All eyes are now on May 7, when Siemens Healthineers reports second-quarter results. Investors will be looking for concrete updates on the diagnostics sale talks and clarity on whether the group can hold its full-year guidance. The company is targeting revenue growth of 5% to 6% and adjusted earnings per share of at least €2.20.

The market expects quarterly revenues of around €6 billion. Beyond the headline numbers, the focus will be on organic growth trends and the impact of global supply chains on margins. Management has also been pushing the digital health agenda, highlighting AI-powered systems that could improve hospital efficiency — a potential growth driver that may gain more attention once the immediate challenges are addressed.

A dividend of €1.01 per share is expected, which would provide some support for the fundamental case. But the real test is whether the company can convince investors that the second half of the year will deliver the strength needed to hit its targets, given the headwinds from China and the US. The answer will determine whether this 52-week low marks a buying opportunity or a warning of further pain to come.